Previous 10 | Next 10 |
home / stock / srpt / srpt articles
Friday, the FDA accepted and filed Sarepta Therapeutics Inc’s (NASDAQ:SRPT) efficacy supplement to the Biologics License Application (BLA) ...
Shares of DoorDash, Inc. (NASDAQ: DASH) fell sharply in today’s session as the company reported mixed financial results for its fourth quart...
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday. Shares of Applied Materials, Inc. (NASDAQ: AMAT) rose sha...
Sarepta Therapeutics Inc (NASDAQ:SRPT) announced data from Part B of the MOMENTUM study (Study SRP-5051-201) Phase 2, multi-ascending dose tri...
Monday, Sarepta Therapeutics Inc (NASDAQ: SRPT) reported preliminary FY23 net product revenue of $1.145 billion. The Cambridge, Mass...
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. Shares of Acuity Brands, Inc. (NYSE: AYI) rose sharply Tuesd...
Needham analyst forecasts a positive outlook for Arcellx Inc (NASDAQ:ACLX) in 2024, citing strong potential stemming from the anticipated pivotal...
NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues investigating potential securitie...
Catalent Inc's (NYSE: CTLT) Q1 FY24 revenue of $982 million decreased 4% as reported, or 6%, in constant currency, beating the consen...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...